In short
Rigosertib Sodium is an investigational drug being studied in clinical trials for various types of cancer and blood disorders. This article summarizes key information about ongoing clinical trials evaluating the safety, efficacy, and optimal dosing of rigosertib in conditions like myelodysplastic syndromes (MDS), leukemias, and solid tumors. The trials are exploring both intravenous and oral formulations of rigosertib across different patient populations.
At a glance
- Drug Name
- Rigosertib Sodium (also known as ON 01910.Na)
- Formulations
- Intravenous infusion, Oral capsules
- Conditions Studied
- Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Advanced solid tumors
- Key Trial Objectives
- Determine safety, optimal dosing, pharmacokinetics, efficacy
- Common Endpoints
- Adverse events, drug concentration in plasma, hematologic improvement, overall response rate, duration of response
- Dosing Strategies
- IV: 24-120 hour continuous infusions, various doses (e.g., 650-4450 mg/m2); Oral: Twice or thrice daily dosing, various doses (e.g., 560 mg BID)
- Patient Populations
- Refractory/relapsed leukemias, high-risk MDS, transfusion-dependent low-risk MDS, advanced solid tumors
What is Rigosertib?
Rigosertib sodium, also known as ON 01910.Na, is an investigational anti-cancer drug that is being studied for its potential to treat various types of cancer and blood disorders. It is a novel small molecule that targets cellular signaling pathways involved in cancer cell growth and survival.
Conditions Treated
Rigosertib is being investigated for the treatment of several conditions, including:
- Myelodysplastic Syndromes (MDS): A group of blood disorders where the bone marrow doesn't produce enough healthy blood cells
- Acute Myeloid Leukemia (AML): A type of blood cancer that starts in the bone marrow
- Acute Lymphoblastic Leukemia (ALL): A type of blood cancer that affects lymphocytes, a type of white blood cell
- Chronic Myeloid Leukemia (CML): A slow-growing type of blood cancer that starts in the bone marrow
- Chronic Lymphocytic Leukemia (CLL): A type of cancer that affects lymphocytes and progresses slowly
- Solid Tumors: Various types of cancers that form solid masses
Administration
Rigosertib can be administered in two main forms:
- Intravenous (IV) Infusion: Rigosertib is given as a continuous infusion over 24 to 72 hours, typically every two weeks. The dosage is usually based on the patient's body surface area (BSA) and can range from 650 mg/m² to 2400 mg/m² per day.
- Oral Capsules: Rigosertib is also available in oral form, typically given as 560 mg in the morning and 280 mg in the afternoon, taken on an empty stomach. The oral form is often given for 21 consecutive days of a 21-day cycle.
Efficacy
Clinical trials have shown promising results for rigosertib in treating various conditions:
- In patients with high-risk MDS who had failed or progressed on hypomethylating agent therapy, rigosertib showed potential to improve overall survival.
- For low-risk MDS patients who were transfusion-dependent and refractory to erythropoiesis-stimulating agents, oral rigosertib demonstrated the potential to reduce transfusion dependency.
- In studies involving patients with various types of leukemia, rigosertib showed anti-tumor activity and potential for improving blood cell counts.
Safety and Side Effects
As with any medication, rigosertib can cause side effects. Common adverse events reported in clinical trials include:
- Fatigue
- Nausea and vomiting
- Diarrhea
- Decreased blood cell counts (which can lead to increased risk of infection, bleeding, or anemia)
- Urinary symptoms (such as dysuria or difficulty urinating)
The severity and frequency of side effects can vary depending on the dosage and method of administration. Researchers are continuously monitoring and evaluating the safety profile of rigosertib in ongoing clinical trials.
Ongoing Research
Rigosertib is still under investigation, and numerous clinical trials are ongoing to further evaluate its efficacy and safety in various cancer types and blood disorders. These studies aim to determine the optimal dosing regimens, identify the most responsive patient populations, and assess long-term outcomes.
Researchers are also studying the drug's mechanism of action, its effects on specific cellular pathways, and its potential combinations with other cancer therapies.
As an investigational drug, rigosertib is not yet approved for general use. Patients interested in accessing rigosertib should consult with their healthcare providers about the possibility of participating in clinical trials.